135:
24:
217:
approval for new products, and selling them to
Canadian customers. Knight is generally not involved in initial drug discovery or development. As of June 2020, the company commercializes dozens of innovative pharmaceuticals in Canada and 10 Latin American countries with a 700+ employees. Knight's
182:
In 2011, Goodman was seriously injured in a cycling accident, forcing him to temporarily relinquish the CEO role to Mark
Beaudet. The accident caused serious traumatic brain injury, although Goodman has almost fully recovered. Also in 2011, Paladin offered to buy Afexa Life Sciences for $ 57
194:, an American pharmaceutical company, acquired most of the assets of Paladin Labs for $ 3 billion, or $ 151 a share, a 100 times increase from its IPO price. As part of the transaction, Knight Therapeutics was spun-off to the shareholders of Paladin, with the rights to
471:
213:
Knight
Therapeutics, like Paladin Labs before it, focuses on marketing and licensing drugs from international drug makers for the Canada and Latin America. This involves getting
351:
476:
302:
159:
that focuses on acquiring or in-licensing innovative pharmaceutical products for the
Canadian and select international markets. It is listed on the
205:
In
November 2016, it was rumored that Endo was considering selling Paladin back to Knight Therapeutics, for less than it initially paid for it.
247:
327:
230:
for the treatment of leishmaniasis and
Burinex for edema associated with congestive heart failure, cirrhosis of the liver and renal disease.
466:
399:
376:
218:
main product portfolios cover Pain/Gastrointestinal, Ophthalmic, Women's Health and
Oncology. Its marketed products are
56:
277:
184:
160:
48:
179:, the predecessor company to Knight Therapeutics. It launched an IPO in that year at $ 1.50 per share.
191:
134:
148:
422:
248:"'If Canada was efficient, I wouldn't exist:' The miraculous success of Jonathan Ross Goodman"
202:
drug. It was also led by
Jonathan Ross Goodman, and was in substantially the same business.
407:
434:
23:
34:
460:
214:
199:
42:
227:
195:
223:
328:"Labopharm shareholders approve $ 20.5 million acquisition by Paladin Labs"
219:
152:
83:
400:"Exclusive: Endo considers sale of Paladin Labs to Knight Therapeutics"
167:), with a market capitalization of $ 1.02 billion as of August 2019.
164:
156:
87:
52:
377:"Can Knight Therapeutics Inc. Repeat the Success of Paladin Labs?"
187:. However, it succeeded in acquiring Labopharm for $ 20 million.
352:"It's early days for Knight Therapeutics, but chemistry is right"
303:"Goodman Rallies From Near-Death Bike Spill for Drug Renaissance"
451:
123:
175:
In 1995, Jonathan Ross
Goodman and Mark Beaudet founded
118:
110:
98:
78:
70:
62:
40:
30:
222:for the treatment of opioid-induced constipation,
472:Companies listed on the Toronto Stock Exchange
226:, a sub-dermal implant for opioid dependence,
8:
16:
104:Jonathan Ross Goodman (Executive Chairman)
133:
22:
15:
278:"Paladin Labs Founder Finds a New Knight"
239:
430:
420:
7:
297:
295:
293:
291:
272:
270:
268:
477:Pharmaceutical companies of Canada
14:
147:is a Canadian public specialty
57:S&P/TSX Composite Component
379:. The Motley Fool. 18 May 2017
1:
467:Companies based in Montreal
183:million, but was outbid by
493:
21:
145:Knight Therapeutics Inc.
114:$ 243.478 million (2021)
17:Knight Therapeutics Inc.
185:Valeant Pharmaceuticals
161:Toronto Stock Exchange
74:Jonathan Ross Goodman
282:The Montreal Gazette
192:Endo Pharmaceuticals
410:on November 5, 2016
398:Reuters Editorial.
106:Samira Sakhia (CEO)
18:
433:has generic name (
356:The Globe and Mail
151:company based in
142:
141:
484:
452:Official Website
439:
438:
432:
428:
426:
418:
416:
415:
406:. Archived from
395:
389:
388:
386:
384:
373:
367:
366:
364:
363:
348:
342:
341:
339:
338:
324:
318:
317:
315:
314:
299:
286:
285:
274:
263:
262:
260:
259:
244:
138:
137:
130:
127:
125:
26:
19:
492:
491:
487:
486:
485:
483:
482:
481:
457:
456:
448:
443:
442:
429:
419:
413:
411:
397:
396:
392:
382:
380:
375:
374:
370:
361:
359:
350:
349:
345:
336:
334:
326:
325:
321:
312:
310:
301:
300:
289:
276:
275:
266:
257:
255:
246:
245:
241:
236:
211:
173:
132:
122:
105:
101:
94:
90:
55:
45:
12:
11:
5:
490:
488:
480:
479:
474:
469:
459:
458:
455:
454:
447:
446:External links
444:
441:
440:
390:
368:
343:
319:
287:
264:
252:Financial Post
238:
237:
235:
232:
210:
207:
172:
169:
149:pharmaceutical
140:
139:
120:
116:
115:
112:
108:
107:
102:
99:
96:
95:
92:
82:
80:
76:
75:
72:
68:
67:
64:
60:
59:
46:
41:
38:
37:
32:
28:
27:
13:
10:
9:
6:
4:
3:
2:
489:
478:
475:
473:
470:
468:
465:
464:
462:
453:
450:
449:
445:
436:
431:|author=
424:
409:
405:
401:
394:
391:
378:
372:
369:
357:
353:
347:
344:
333:
329:
323:
320:
308:
307:Bloomberg.com
304:
298:
296:
294:
292:
288:
284:. 2014-04-01.
283:
279:
273:
271:
269:
265:
253:
249:
243:
240:
233:
231:
229:
225:
221:
216:
215:Health Canada
208:
206:
203:
201:
200:leishmaniasis
197:
193:
188:
186:
180:
178:
170:
168:
166:
162:
158:
154:
150:
146:
136:
129:
121:
117:
113:
109:
103:
97:
89:
85:
81:
77:
73:
69:
65:
61:
58:
54:
50:
47:
44:
39:
36:
33:
29:
25:
20:
412:. Retrieved
408:the original
403:
393:
381:. Retrieved
371:
360:. Retrieved
358:. 2014-09-04
355:
346:
335:. Retrieved
331:
322:
311:. Retrieved
309:. 2017-07-31
306:
281:
256:. Retrieved
254:. 2017-07-31
251:
242:
212:
204:
189:
181:
177:Paladin Labs
176:
174:
144:
143:
79:Headquarters
31:Company type
332:Global News
461:Categories
414:2018-01-20
383:19 January
362:2018-01-19
337:2018-01-20
313:2018-01-20
258:2018-01-20
234:References
224:Probuphine
124:gud-knight
100:Key people
423:cite news
190:In 2014,
43:Traded as
228:Impavido
220:Movantik
209:Business
196:Impavido
163:(symbol
153:Montreal
84:Montreal
171:History
119:Website
111:Revenue
71:Founder
63:Founded
51::
157:Quebec
131:
93:Canada
88:Quebec
35:Public
435:help
385:2018
198:, a
126:.com
66:1995
165:GUD
128:/en
53:GUD
49:TSX
463::
427::
425:}}
421:{{
404:CA
402:.
354:.
330:.
305:.
290:^
280:.
267:^
250:.
155:,
91:,
86:,
437:)
417:.
387:.
365:.
340:.
316:.
261:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
